Company / EPS (Basic)
Inhibrx Biosciences, Inc. EPS (Basic) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$114.01
FY2025
5-year range
-$20.48 / $114.01
FY2023-FY2025
Trend
+656.7%
vs FY2024
Sector context
#1 of 208
Health Care
What the data says
EPS (Basic) changed +657% YoY in FY2025, a notable deviation from the 2-year average annual change of +328%.
Based on SEC 10-K filings.
114.01 in FY2025. Ranks 1st among 208 companies in Health Care.
Improved from $-20.48 to $114.01 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 208This company $114.01 Sector average -$0.87
▼
+13195.2% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 656.7% year-over-year.
- Ranks #1 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.01 | +656.7% |
| FY2024 | -$20.48 | +0.0% |
| FY2023 | -$20.48 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026